Kyongbo Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.58%

Kyongbo Pharmaceutical Co Ltd (214390) has an Asset Resilience Ratio of 0.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Kyongbo Pharmaceutical Co Ltd (214390) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩1.83 Billion
≈ $1.24 Million USD Cash + Short-term Investments

Total Assets

₩316.49 Billion
≈ $214.48 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Kyongbo Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Kyongbo Pharmaceutical Co Ltd balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Kyongbo Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 214390 company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩1.83 Billion 0.58%
Total Liquid Assets ₩1.83 Billion 0.58%

Asset Resilience Insights

  • Limited Liquidity: Kyongbo Pharmaceutical Co Ltd maintains only 0.58% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Kyongbo Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Kyongbo Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Huadong Medicine Co Ltd
SHE:000963
Drug Manufacturers - Specialty & Generic 0.05%
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
Drug Manufacturers - Specialty & Generic -0.89%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
Drug Manufacturers - Specialty & Generic -2.56%
Celltrion Pharm Inc
KQ:068760
Drug Manufacturers - Specialty & Generic 12.49%
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
Drug Manufacturers - Specialty & Generic 0.40%

Annual Asset Resilience Ratio for Kyongbo Pharmaceutical Co Ltd (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Kyongbo Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.70% ₩2.00 Billion
≈ $1.36 Million
₩283.89 Billion
≈ $192.39 Million
+0.38pp
2023-12-31 0.33% ₩870.00 Million
≈ $589.59K
₩266.31 Billion
≈ $180.47 Million
-0.03pp
2022-12-31 0.36% ₩870.00 Million
≈ $589.59K
₩240.54 Billion
≈ $163.01 Million
+0.85pp
2021-12-31 -0.49% ₩-1.16 Billion
≈ $-786.85K
₩236.98 Billion
≈ $160.60 Million
-4.26pp
2020-12-31 3.77% ₩9.54 Billion
≈ $6.47 Million
₩253.24 Billion
≈ $171.62 Million
+4.21pp
2019-12-31 -0.44% ₩-1.05 Billion
≈ $-713.64K
₩237.82 Billion
≈ $161.17 Million
+0.27pp
2018-12-31 -0.71% ₩-1.58 Billion
≈ $-1.07 Million
₩221.62 Billion
≈ $150.19 Million
-0.07pp
2017-12-31 -0.64% ₩-1.32 Billion
≈ $-895.45K
₩204.87 Billion
≈ $138.84 Million
--
pp = percentage points

About Kyongbo Pharmaceutical Co Ltd

KO:214390 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$90.40 Million
₩133.40 Billion KRW
Market Cap Rank
#19680 Global
#1015 in Korea
Share Price
₩5580.00
Change (1 day)
+1.64%
52-Week Range
₩4765.00 - ₩8550.00
All Time High
₩19100.23
About

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more